Erratum to: Detection of ATM germline variants by the p53 mitotic centrosomal localization test in BRCA1/2-negative patients with early-onset breast cancer
نویسندگان
چکیده
Author details Unit of Cellular Networks and Molecular Therapeutic Targets, Department of Research, Advanced Diagnostic, and Technological Innovation, Regina Elena National Cancer Institute – IRCCS, Via Elio Chianesi 53, 00144 Rome, Italy. Istituto Pasteur-Fondazione Cenci Bolognetti, Department of Molecular Medicine, University La Sapienza, Rome, Italy. Endocrinology Unit, Department of Clinical and Experimental Oncology, Regina Elena National Cancer Institute – IRCCS, Rome, Italy. Department of Molecular Medicine, University La Sapienza, Rome, Italy. Department of Clinical and Molecular Medicine, University La Sapienza, Laboratorio di Ricerca Biomedica, Fondazione Università Niccolò Cusano per la Ricerca Medico Scientifica, Rome, Italy. Radiotherapy Unit, Department of Research, Advanced Diagnostic, and Technological Innovation, Regina Elena National Cancer Institute IRCCS, Rome, Italy. Medical Physics Unit, Department of Research, Advanced Diagnostic, and Technological Innovation, Regina Elena National Cancer Institute – IRCCS, Rome, Italy. Toracic Surgery Unit, Department of Clinical and Experimental Oncology, Regina Elena National Cancer Institute – IRCCS, Rome, Italy. Hepato-pancreato-biliary Surgery Unit, Department of Clinical and Experimental Oncology, Regina Elena National Cancer Institute – IRCCS, Rome, Italy. Gynecological Oncology Unit, Department of Clinical and Experimental Oncology, Regina Elena National Cancer Institute – IRCCS, Rome, Italy. Department of Experimental Medicine, Sapienza University of Rome, Policlinico Umberto I, Viale Regina Elena, 32400161 Rome, Italy.
منابع مشابه
Detection of ATM germline variants by the p53 mitotic centrosomal localization test in BRCA1/2-negative patients with early-onset breast cancer
BACKGROUND Variant ATM heterozygotes have an increased risk of developing cancer, cardiovascular diseases, and diabetes. Costs and time of sequencing and ATM variant complexity make large-scale, general population screenings not cost-effective yet. Recently, we developed a straightforward, rapid, and inexpensive test based on p53 mitotic centrosomal localization (p53-MCL) in peripheral blood mo...
متن کاملMinor role of BRCA2 mutation (Exon2 and Exon11) in patients with early-onset breast cancer amongst Iranian Azeri-Turkish women
Objective(s): Breast cancer is the most common cancer in women. Every year, one million new cases are reported worldwide, representing 18% of the total number of cancer in women. Hereditary BRCA1 and BRCA2 mutations account for about 60% of inherited breast cancer and are the only known causes of hereditary breast cancer syndrome. The aim of this study was to determine the frequency of BRCA2 (e...
متن کاملComprehensive Analysis of BRCA1, BRCA2 and TP53 Germline Mutation and Tumor Characterization: A Portrait of Early-Onset Breast Cancer in Brazil
Germline mutations in BRCA1, BRCA2 and TP53 genes have been identified as one of the most important disease-causing issues in young breast cancer patients worldwide. The specific defective biological processes that trigger germline mutation-associated and -negative tumors remain unclear. To delineate an initial portrait of Brazilian early-onset breast cancer, we performed an investigation combi...
متن کاملp53 centrosomal localization diagnoses ataxia-telangiectasia homozygotes and heterozygotes.
Ataxia-telangiectasia (A-T) is an autosomal recessive neurodegenerative disorder characterized by radiosensitivity, genomic instability, and predisposition to cancer. A-T is caused by biallelic mutations in the ataxia-telangiectasia mutated (ATM) gene, but heterozygous carriers, though apparently healthy, are believed to be at increased risk for cancer and more sensitive to ionizing radiation t...
متن کاملPrevalence and Prognostic Role of BRCA1/2 Variants in Unselected Chinese Breast Cancer Patients
BACKGROUND The prevalence of BRCA1/2 variants in Chinese breast cancer patients varies among studies. Germline or somatic BRCA1/2 mutations are associated with sensitivity to poly(ADP-ribose) polymerase-1 inhibitors and DNA-damaging agents. We aimed to investigate the distribution of both somatic and germline BRCA1/2 variants in unselected Chinese breast cancer patients, and explore their roles...
متن کامل